Initiative aims to understand Variability in Cell Culture Media
Expansive facilities at NIBRT

News

Initiative aims to understand Variability in Cell Culture Media

25 Mar, 2022

Published over 4 years ago. See the latest and most current information on News.

NIBRT, Kerry Group and ValitaCell are collaborating on a strategic initiative to validate the role of protein hydrolysates in cell culture media during the commercial manufacture of biotherapeutics. The manufacturing process at a commercial scale involves the growth of mammalian cells in a multi-component liquid media and Kerry has commercialised protein hydrolysates from various sources as bioactive components to be used in mammalian cell cultures for this purpose.   

The raw material for the production of these hydrolysates includes a variety of plant and microbial sources such as soy, yeast, cotton and wheat. However, the variability in the performance of these hydrolysates is not well understood; the hydrolysates are chemically undefined and contain complex composition dependent on the raw material used. The challenge for the biopharmaceutical industry is that cell culture media is one of the most difficult components to control. This initiative, which is supported by Enterprise Ireland under the Innovation Partnership programme, will use ViltaCell’s ChemStress® platform to characterise the behaviour of cells using a panel of specific, small molecule chemical stressors.  The assay is carried out on a multiwell plate and enables the rapid screening of the robustness of cells within the specific environment of each well.

The programme of work is to be conducted at NIBRT facilities under the guidance of Prof. Michael Butler.

“ValitaCell have invested significant resources in our ChemStress® platform to provide scientists with a Biological prism of their manufacturing environment, in microscale. Working with Kerry Group and NIBRT on this specific validation problem is a great opportunity to demonstrate the power of our technology in the Cell Culture media component sector,” said Dr. Jerry Clifford, CEO at ValitaCell.

“We are delighted at NIBRT to receive funding from Enterprise Ireland in collaboration with the Kerry Group and ValitaCell to enable a study of the bioactive properties of plant and microbial sourced hydrolysates using the ChemStress® platform technology.  This research will enable an understanding of the functional role of hydrolysates in cell culture media that will promote the efficient production of biotherapeutics from bioprocesses,” commented  Prof Michael Butler, Principal Investigator in the Cell Technology Group at NIBRT.

More information online

Latest News

ILM 51.5 July 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Exhibitor registration opens for 2027 occupational safety and health trade fair in Düsseldorf
Explore more Arrow
Pollution Solutions Online
Energy efficiency first: Why shipping must act now while low-GHG fuels scale
Explore more Arrow
Petro Online
UK refining capacity falls to four plants after a second unplanned closure
Explore more Arrow
Chromatography Today
SLAS Technology Volume 38 highlights AI-driven laboratory automation, transcriptomics and gene therapy
Explore more Arrow